News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
European Commission Awards Orphan Designation to Knopp NeuroSciences’ KNS-760704 in ALS
March 10, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PITTSBURGH--(BUSINESS WIRE)--Knopp Neurosciences Inc. (“Knopp”) today announced that the European Commission (“EC”) has designated KNS-760704 as an orphan medicinal product for the treatment of Amyotrophic Lateral Sclerosis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
·
1 min read
·
Lori Ellis
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
·
2 min read
·
Tristan Manalac
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
·
3 min read
·
Heather McKenzie
